Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis

被引：0
|
作者：
Jessica Ailani
Jeffrey Scott Andrews
Antje Tockhorn-Heidenreich
Richard Wenzel
Mallikarjuna Rettiganti
机构：
[1] Medstar Georgetown University,
[2] Eli Lilly and Company,undefined
来源：
Advances in Therapy | 2022年 / 39卷
关键词：
CONQUER trial; Galcanezumab; Migraine; Prior preventive failures; Total pain burden;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4544 / 4555
页数：11
相关论文
共 50 条
  • [1] Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis
    Ailani, Jessica
    Andrews, Jeffrey Scott
    Tockhorn-Heidenreich, Antje
    Wenzel, Richard
    Rettiganti, Mallikarjuna
    ADVANCES IN THERAPY, 2022, 39 (10) : 4544 - 4555
  • [2] Efficacy of Galcanezumab in Patients Who Had Not Previously Benefited from Commonly Prescribed Migraine Preventive Treatments
    Kuruppu, D.
    Tobin, J. A.
    Dong, Y.
    Aurora, S.
    Yunes-Medina, L.
    Green, L.
    HEADACHE, 2020, 60 : 106 - 106
  • [3] Efficacy of Galcanezumab in Patients Who Had Not Benefited From Commonly Prescribed Migraine Preventive Treatments
    Kuruppu, Dulanji
    ANNALS OF NEUROLOGY, 2020, 88 : S152 - S153
  • [4] Total Pain Burden in Patients with Treatment-Resistant Migraine: Effects of Galcanezumab in the CONQUER Phase 3B Trial
    Ailani, Jessica
    Andrews, J. Scott
    Tockhorn-Heidenreich, Antje
    Wenzel, Richard
    Rettiganti, Mallikarjuna
    ANNALS OF NEUROLOGY, 2021, 90 : S137 - S137
  • [5] Total pain burden in patients with treatment-resistant migraine: effects of galcanezumab in the CONQUER Phase 3b trial
    Ailani, J.
    Andrews, J.
    Tockhorn-Heidenreich, A.
    Wenzel, R.
    Rettiganti, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 272 - 272
  • [6] Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
    Uwe Reuter
    Christian Lucas
    David Dolezil
    Austin L. Hand
    Martha D. Port
    Russell M. Nichols
    Chad Stroud
    Antje Tockhorn-Heidenreich
    Holland C. Detke
    Advances in Therapy, 2021, 38 : 5465 - 5483
  • [7] Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study
    Rose Okonkwo
    Antje Tockhorn-Heidenreich
    Chad Stroud
    Marie-Ange Paget
    Manjit S. Matharu
    Cristina Tassorelli
    The Journal of Headache and Pain, 2021, 22
  • [8] Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
    Reuter, Uwe
    Lucas, Christian
    Dolezil, David
    Hand, Austin L.
    Port, Martha D.
    Nichols, Russell M.
    Stroud, Chad
    Tockhorn-Heidenreich, Antje
    Detke, Holland C.
    ADVANCES IN THERAPY, 2021, 38 (11) : 5465 - 5483
  • [9] Efficacy of galcanezumab in patients with migraine and history of failure to 3-4 preventive medication categories: subgroup analysis from CONQUER study
    Okonkwo, Rose
    Tockhorn-Heidenreich, Antje
    Stroud, Chad
    Paget, Marie-Ange
    Matharu, Manjit S.
    Tassorelli, Cristina
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [10] Efficacy and Safety of Galcanezumab as a Preventive Treatment for Episodic Migraine in South Korean Patients: A Post-Hoc Analysis of a Phase 3 Clinical Trial
    Kim, Byung-Kun
    Cho, Soo-Jin
    Han, Jeong Hee
    Dell'Agnello, Grazia
    Panni, Tommaso
    Kim, Manho
    Oh, Kyungmi
    Moon, Heui-Soo
    Chu, Min Kyung
    JOURNAL OF CLINICAL NEUROLOGY, 2023, 19 (05): : 483 - 494
12345